[go: up one dir, main page]

PE20080153A1 - Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) - Google Patents

Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)

Info

Publication number
PE20080153A1
PE20080153A1 PE2007000698A PE2007000698A PE20080153A1 PE 20080153 A1 PE20080153 A1 PE 20080153A1 PE 2007000698 A PE2007000698 A PE 2007000698A PE 2007000698 A PE2007000698 A PE 2007000698A PE 20080153 A1 PE20080153 A1 PE 20080153A1
Authority
PE
Peru
Prior art keywords
cgrp
antagonist
pharmaceutical composition
calcitonin gene
composition including
Prior art date
Application number
PE2007000698A
Other languages
English (en)
Inventor
Henri Doods
Kirsten Arndt
Thierry Bouyssou
Stephan Georg Muller
Klaus Rudolf
Gerhard Schanzle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080153A1 publication Critical patent/PE20080153A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTAGONISTA DEL PEPTIDO RELACIONADO CON EL GEN CALCITONINA (CGRP) COMO PRINCIPIO ACTIVO DE FORMULA (I), (II), (III), ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.1 A 90% EN PESO DE LA COMPOSICION; B) UN DILUYENTE TAL COMO CARBONATO CALCICO, LACTOSA, ENTRE OTROS; C) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO. DICHA COMPOSICION ES DE ADMINISTRACION ORAL SIENDO UTIL EN EL TRATAMIENTO DE REFLUJO GASTRO-ESOFAGICO, DISPEPSIA, ENFERMEDAD DE CROHN, COLITIS ULCEROSA
PE2007000698A 2006-06-08 2007-06-06 Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) PE20080153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08

Publications (1)

Publication Number Publication Date
PE20080153A1 true PE20080153A1 (es) 2008-04-14

Family

ID=37101671

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000698A PE20080153A1 (es) 2006-06-08 2007-06-06 Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
PE2007000697A PE20080370A1 (es) 2006-06-08 2007-06-06 Derivados de quinazolinona como antagonistas de cgrp

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000697A PE20080370A1 (es) 2006-06-08 2007-06-06 Derivados de quinazolinona como antagonistas de cgrp

Country Status (19)

Country Link
US (2) US7807666B2 (es)
EP (2) EP2029233A2 (es)
JP (2) JP2009539799A (es)
KR (1) KR20090021214A (es)
CN (1) CN101500653A (es)
AR (2) AR061272A1 (es)
AU (1) AU2007255395A1 (es)
BR (1) BRPI0712492A2 (es)
CA (2) CA2654048A1 (es)
CL (2) CL2007001662A1 (es)
EA (1) EA200802381A1 (es)
EC (1) ECSP089025A (es)
IL (1) IL195712A0 (es)
MX (1) MX2008015562A (es)
NO (1) NO20085051L (es)
PE (2) PE20080153A1 (es)
TW (2) TW200808791A (es)
UY (2) UY30398A1 (es)
WO (2) WO2007141285A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654048A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp antagonists
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
PL2710039T3 (pl) 2011-05-20 2019-07-31 Alderbio Holdings Llc Kompozycje przeciwko CGRP i ich zastosowanie
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005041757A2 (en) * 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101146799A (zh) 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
CA2654048A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp antagonists

Also Published As

Publication number Publication date
MX2008015562A (es) 2008-12-17
WO2007141284A3 (en) 2008-03-06
EP2029234A1 (en) 2009-03-04
JP2009539799A (ja) 2009-11-19
US20080139537A1 (en) 2008-06-12
TW200815010A (en) 2008-04-01
IL195712A0 (en) 2009-09-01
PE20080370A1 (es) 2008-06-13
UY30399A1 (es) 2008-01-31
TW200808791A (en) 2008-02-16
WO2007141285A1 (en) 2007-12-13
CL2007001663A1 (es) 2008-01-25
WO2007141284A2 (en) 2007-12-13
CN101500653A (zh) 2009-08-05
NO20085051L (no) 2008-12-19
CA2654047A1 (en) 2007-12-13
EP2029233A2 (en) 2009-03-04
KR20090021214A (ko) 2009-02-27
UY30398A1 (es) 2008-01-31
US20080139591A1 (en) 2008-06-12
BRPI0712492A2 (pt) 2012-08-21
AR061271A1 (es) 2008-08-13
AU2007255395A1 (en) 2007-12-13
CA2654048A1 (en) 2007-12-13
US7807666B2 (en) 2010-10-05
EA200802381A1 (ru) 2009-06-30
JP2009539800A (ja) 2009-11-19
CL2007001662A1 (es) 2008-01-25
AR061272A1 (es) 2008-08-13
ECSP089025A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
PE20130340A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp)
ECSP13012474A (es) Forma de dosificación resistente a manipulación que comprende una sal inorgánica
AR077638A1 (es) Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
ECSP13012812A (es) Formulaciones inmunosupresoras
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
ECSP12011958A (es) Composiciones farmacéuticas que comprenden ligandos de receptores sigma
PE20220751A1 (es) Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
ECSP12011699A (es) Tableta
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
CR20110209A (es) Composición farmacéutica sólida
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
PE20110706A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
MX357611B (es) Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
PE20091777A1 (es) Dronedarona o una sal aceptable farmaceuticamente de la misma

Legal Events

Date Code Title Description
FC Refusal